Yıl: 2023 Cilt: 30 Sayı: 2 Sayfa Aralığı: 194 - 198 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2022.10.305 İndeks Tarihi: 04-04-2023

Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation

Öz:
Aim: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, but it is so aggressive that is the third most common cause of cancer related death. We aim to study the role of PLR in prognosis of HCC and to see if it can be a predictor of overall survival and disease-free survival among HCC patients that received liver transplantation in our center. Materials and Methods: This is a single center retrospective analysis of prospectively collected data. The study was carried out in liver transplant institute of Inonu University, Malatya, Turkey. Consecutive patients that received liver transplantation for HCC and survive for at least 90 days post transplantation were included in the study. Data was collected regarding age, gender, presence or absence of cirrhosis, cause of cirrhosis, number of nodules, maximum size of the tumor, preoperative PLR, pre-transplant GGT, type of transplant, presence or absence of microvascular invasion, overall survival and disease-free survival. The study was censored on June 2022. Data was analyzed using SPSS version 25. Results: Platelet lymphocyte ratio was found to be significantly associated with some poor prognostic factors of HCC in our patients. We found that PLR is significantly associated with maximum tumor diameter (MTD) and total tumor diameter (TTD) with p= <0.0001 and 0.0016 respectively. Univariate analysis revealed that PLR is a predictor of worse DFS or OS but when subjected to multivariate analysis, we found that PLR is not an independent predictor of OS and DFS. Conclusion: Platelet lymphocyte ratio is associated with poor prognostics feature of hepatocellular carcinoma.
Anahtar Kelime: Platelet lymphocyte ratio Hepatocellular carcinoma Prognosis Liver transplantation

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Mak L, Cruz-ramón V, Chinchilla-lópez P, Torres HA, Merrill JK, Bailey HH, et al. Global Epidemiol- ogy , Prevention , and Management of Global Epi- demiology of HBV [Internet]. 2019. Available from: http://ascopubs.org/doi/pdfdirect/10.1200/EDBK_200939.
  • 2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim [Internet] 2021;7(6). Available from: http://dx.doi.org/10.1038/s41572-020-00240-3.
  • 3. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocel- lular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) 2017;96(9).
  • 4. Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016;6(1):21–36.
  • 5. Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) 2008;21(3):266–80.
  • 6. Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. Hpb 2005;7(1):42–9.
  • 7. Poon RTP, Sheung TF, Chung M Lo, Chi LL, Wong J. Long- term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver func- tion: Implications for a strategy of salvage transplantation. Ann Surg 2002;235(3):373–82.
  • 8. Wang W, Guo Y, Zhong J, Wang Q, Wang X, Wei H, et al. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocel- lular carcinoma. Sci Rep [Internet] 2021;11(1):1–10. Available from: https://doi.org/10.1038/s41598-021-82058-x.
  • 9. Hu H, Qi S, Zeng S, Zhang P, He L, Wen S, et al. Im- portance of Microvascular Invasion Risk and Tumor Size on Recurrence and Survival of Hepatocellular Carcinoma After Anatomical Resection and Non-anatomical Resection. Front On- col 2021;11(March).
  • 10. Cuccurullo V, Di Stasio GD, Mazzarella G, Cascini GL. Mi- crovascular Invasion in HCC: The Molecular Imaging Perspec- tive. Contrast Media Mol Imaging 2018;2018.
  • 11. Varki A. Trousseau’s syndrome: Multiple definitions and multi- ple mechanisms. Blood 2007;110(6):1723–9.
  • 12. Palacios-Acedo AL, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy. Front Immunol 2019;10(July):1805.
  • 13. Braun A, Anders HJ, Gudermann T, Mammadova-Bach E. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. Front Oncol 2021;11(July):1–27.
  • 14. Zhang YY, Li WQ, Li ZF, Guo XH, Zhou SK, Lin A, et al. Higher levels of pre-operative peripheral lymphocyte count is a favorable prognostic factor for patients with stage I and II rectal cancer. Front Oncol 2019;9(SEP).
  • 15. Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng J, et al. Prog- nostic role of pretreatment blood lymphocyte count in patients with solid tumors: A systematic review and meta-analysis. Can- cer Cell Int 2020;20(1):1–14.
  • 16. Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng B Bin, et al. Prognostic role of platelet-to-lymphocyte ratio in hep- atocellular carcinoma with different BCLC Stages: A systematic review and meta-analysis. Gastroenterol Res Pract 2018;2018.
  • 17. Yang HJ, Jiang JH, Liu QA, Zhou CM, Du YF, Wu T, et al. Pre- operative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection. Tumor Biol 2017;39(6).
  • 18. Zheng J, Cai J, Li H, Zeng K, He L, Fu H, et al. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prog- nostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: A Meta-Analysis and Systematic Review. Cell Physiol Biochem 2017;44(3):967–81.
  • 19. Ince V, Akbulut S, Otan E, Ersan V, Karakas S, Sahin TT, et al. Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. J Gastrointest Cancer 2020;51(3):998–1005.
  • 20. Ince V, Carr BI, Bag HG, Ersan V, Usta S, Koc C, et al. Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha- fetoprotein, a retrospective cohort study. World J Gastrointest Surg 2020;12(12):468–563.
  • 21. Wu G, Wu J, Wang B, Zhu X, Shi X, Ding Y. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: A population-based study. Cancer Manag Res 2018;10:4401–10.
  • 22. Thuluvath PJ. Vascular invasion is the most important predictor of survival in HCC, but how do we find it? J Clin Gastroenterol 2009;43(2):101–2.
  • 23. Akkiz H, Carr BI, Yalçln KK, Guerra V, Kuran S, Altlntaş E, et al. Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients. Oncol 2018;94(2):116–24.
  • 24. Carr BI, Guerra V, Donghia R, Yilmaz S. Tumor mul- tifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes. Ann Med Surg [Internet] 2021;66(June):102458. Available from: https://doi.org/10.1016/j.amsu.2021.102458.
  • 25. Chen Y, Zeng J, Guo P, Zeng J, Liu J. Prognostic significance of platelet-to-lymphocyte ratio (Plr) in extrahepatic metastasis of hepatocellular carcinoma after curative resection. Cancer Manag Res 2021;13:1395–405.
  • 26. Yang Y, Wang MC, Tian T, Huang J, Yuan SX, Liu L, et al. A High Preoperative Platelet-Lymphocyte Ratio Is a Neg- ative Predictor of Survival After Liver Resection for Hepati- tis B Virus-Related Hepatocellular Carcinoma: A Retrospective Study. Front Oncol 2020;10(October):1–12.
  • 27. Xia W, Ke Q, Wang Y, Wang W, Zhang M, Shen Y, et al. Pre- dictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. World J Surg Oncol 2015;13(1):1–7.
  • 28. Karaoğullarından Ü, Akkiz H, Kuran S, Uskudar O, Taskay- natan H, Delik A. The Relationship Between Thrombocyte Lym- phocyte Ratio With Tumor Morphology and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma. Turkish J Fam Med Prim Care 2020;14(2):230–5.
  • 29. Suner A, Carr BI. Platelet-to-lymphocyte and neutrophil- to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study. Ann Med Surg [Internet] 2020;58(September):167–71. Available from: https://doi.org/10.1016/j.amsu.2020.08.042.
  • 30. Suner A, I. Carr B, Akkiz H, Uskudar O, Kuran S, Tokat Y, et al. Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics. J Transl Sci 2018;5(3):1–6.
  • 31. Ker C-G, Tong H-Y, Yang M-Y, Tseng I-T, Chang D-M, Chen H-Y, et al. Role of Pre-Operative of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in Prognosis of Hepatocellular Carcinoma. Int J Clin Med 2020;11(09):491–503.
  • 32. Parisi I, Tsochatzis E, Wijewantha H, Rodriguez-Peralvarez M, De Luca L, Manousou P, et al. Inflammation-Based Scores Do Not Predict Post-transplant Recurrence of Hepatocellular Car- cinoma in Patients Within Milan Criteria. Liver Transplant 2014;20(5):1327–35.
  • 33. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepa- tocellular cancer. Transpl Int 2014;27(1):32–41.
  • 34. Tian XC, Liu XL, Zeng FR, Chen Z, Wu DH. Platelet-to- lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who re- ceived transarterial chemoembolization. Eur Rev Med Pharma- col Sci 2016;20(11):2302–9.
  • 35. Xu Y, Yuan X, Zhang X, Hu W, Wang Z, Yao L, et al. Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma. Medicine (Baltimore) 2021;100(25):e26506.
APA Garzali I, Hargura A, ince v, usta s, aloun a, Carr B, Yilmaz S (2023). Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. , 194 - 198. 10.5455/annalsmedres.2022.10.305
Chicago Garzali Ibrahim Umar,Hargura Abdirahman Sakulen,ince volkan,usta sertaç,aloun ali,Carr Brian,Yilmaz Sezai Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. (2023): 194 - 198. 10.5455/annalsmedres.2022.10.305
MLA Garzali Ibrahim Umar,Hargura Abdirahman Sakulen,ince volkan,usta sertaç,aloun ali,Carr Brian,Yilmaz Sezai Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. , 2023, ss.194 - 198. 10.5455/annalsmedres.2022.10.305
AMA Garzali I,Hargura A,ince v,usta s,aloun a,Carr B,Yilmaz S Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. . 2023; 194 - 198. 10.5455/annalsmedres.2022.10.305
Vancouver Garzali I,Hargura A,ince v,usta s,aloun a,Carr B,Yilmaz S Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. . 2023; 194 - 198. 10.5455/annalsmedres.2022.10.305
IEEE Garzali I,Hargura A,ince v,usta s,aloun a,Carr B,Yilmaz S "Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation." , ss.194 - 198, 2023. 10.5455/annalsmedres.2022.10.305
ISNAD Garzali, Ibrahim Umar vd. "Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation". (2023), 194-198. https://doi.org/10.5455/annalsmedres.2022.10.305
APA Garzali I, Hargura A, ince v, usta s, aloun a, Carr B, Yilmaz S (2023). Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. Annals of Medical Research, 30(2), 194 - 198. 10.5455/annalsmedres.2022.10.305
Chicago Garzali Ibrahim Umar,Hargura Abdirahman Sakulen,ince volkan,usta sertaç,aloun ali,Carr Brian,Yilmaz Sezai Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. Annals of Medical Research 30, no.2 (2023): 194 - 198. 10.5455/annalsmedres.2022.10.305
MLA Garzali Ibrahim Umar,Hargura Abdirahman Sakulen,ince volkan,usta sertaç,aloun ali,Carr Brian,Yilmaz Sezai Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. Annals of Medical Research, vol.30, no.2, 2023, ss.194 - 198. 10.5455/annalsmedres.2022.10.305
AMA Garzali I,Hargura A,ince v,usta s,aloun a,Carr B,Yilmaz S Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. Annals of Medical Research. 2023; 30(2): 194 - 198. 10.5455/annalsmedres.2022.10.305
Vancouver Garzali I,Hargura A,ince v,usta s,aloun a,Carr B,Yilmaz S Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation. Annals of Medical Research. 2023; 30(2): 194 - 198. 10.5455/annalsmedres.2022.10.305
IEEE Garzali I,Hargura A,ince v,usta s,aloun a,Carr B,Yilmaz S "Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation." Annals of Medical Research, 30, ss.194 - 198, 2023. 10.5455/annalsmedres.2022.10.305
ISNAD Garzali, Ibrahim Umar vd. "Prognostic role of platelet lymphocyte ratio (PLR) among patients with hepatocellular carcinoma undergoing liver transplantation". Annals of Medical Research 30/2 (2023), 194-198. https://doi.org/10.5455/annalsmedres.2022.10.305